Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease

Next Previous
Trial Profile

A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK 5475 (Primary)
  • Indications Chronic obstructive pulmonary disease; Pulmonary hypertension
  • Focus Therapeutic Use
  • Acronyms INSIGNIA-PH-COPD
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

Most Recent Events

  • 16 May 2025 According to an Merck Sharp and Dohme media release, company announced data from this trial on pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Societys (ATS) 2025 International Conference in San Francisco from May 16-21.
  • 24 Dec 2024 Planned End Date changed from 23 Mar 2028 to 7 Oct 2029.
  • 30 Jan 2024 Planned End Date changed from 15 Sep 2026 to 23 Mar 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top